Barely Significant
← all excerpts

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.

Vaccine · 2022 · PMC9273612 · PMID 35868948

Europe PMCDOI
1
hedged sentence
0.0590
closest p · 1.2× alpha
0.0590
boldest claim

The sentences

did not reach statistical significancep = 0.059so close (0.05 < p ≤ 0.1)
This trend did not reach statistical significance (p = 0.059). 4 Discussion Seroconversion rates, antibody response magnitude and neutralisation were consistently robust across gender, ethnicity, and most age groups after 2 doses of the BNT162b2 mRNA COVID-19 vaccine in this cohort of New Zealanders, enriched for older adults, Māori and Pacific peoples.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.